Salt AI just closed a $10 million pre-Series A, led by Morpheus Ventures with Struck Capital doubling down and Marbruck Investments and CoreWeave stepping in. Add that to the $3 million seed in December 2024, and you’ve got $13 million total raised with a pre-Series A valuation of $29 million. For a company founded in 2023, that’s not momentum, it’s velocity.
Aber Whitcomb and Jim Benedetto are not newcomers to the scaling game. Whitcomb co-founded MySpace and Jam City, bringing serious math and computer science chops from the University of Washington. Benedetto was SVP of Technology at MySpace, later co-founded Gravity, and helped drive Core Scientific. These two saw the gap in enterprise AI long before the hype: workflows were too siloed, too opaque, and too slow for industries where every delay costs time, money, or lives. Salt AI was built to change that.
This isn’t another black-box AI platform whispering “trust us.” Salt AI is contextual, collaborative, and transparent. A visual-first drag-and-drop system makes AI workflows accessible to non coders, while full code options keep the engineers happy. It’s a workspace where scientists, business leaders, and developers can build, deploy, and scale AI workflows in real time. Call it orchestration, call it collaboration, the point is that it actually works across the enterprise.
And the performance isn’t hypothetical. Salt AI has pushed AlphaFold2 to run 22x faster than commercial versions. In partnership with the Ellison Medical Institute, led by Dr. David Agus, Salt AI has already advanced two protein candidates to wet-lab studies after positive in vitro results. Thousands of compounds have been designed and analyzed on the platform. That’s not slideware, that’s science accelerating in front of us.
The leadership bench runs deep. Alex Duffy, VP of AI, Charlie Basil, EVP of Operations, and Nate Beyor, Head of Life Sciences with a PhD in Bioengineering from UC Berkeley and a BS from Yale, are driving execution. Brian Venturo of CoreWeave brings infrastructure muscle to the board. Salt’s 20-person team is scaling global engineering talent to meet demand from biopharma and healthcare giants.
The $10 million raise isn’t just capital, it’s fuel for expansion. Salt AI is doubling down on life sciences and healthcare, building out Salt Matrix to broaden integrations, enhancing diffusion model performance, and delivering enterprise deployment options from private cloud to air-gapped setups. With more than half of pharma and biotech companies prioritizing AI to speed up R&D, the demand is here and growing.
Salt AI isn’t selling shiny tools. It’s selling clarity, speed, and collaboration in markets that can’t afford guesswork. When the noise clears, this platform could be the one holding the baton, turning scattered AI efforts into outcomes that matter.
